Suppr超能文献

阿片类物质使用障碍患者中抑郁症与美沙酮和丁丙诺啡治疗结果:一项文献综述

Depression and Outcomes of Methadone and Buprenorphine Treatment Among People with Opioid Use Disorders: A Literature Review.

作者信息

Ghabrash Maykel Farag, Bahremand Arash, Veilleux Martine, Blais-Normandin Geneviève, Chicoine Gabrielle, Sutra-Cole Catherine, Kaur Navdeep, Ziegler Daniela, Dubreucq Simon, Juteau Louis-Christophe, Lestage Laurent, Jutras-Aswad Didier

机构信息

Centre de Recherche, Centre Hospitalier, Université de Montréal (CRCHUM), Montréal, Canada.

Department of Psychiatry and Addictology, Université de Montréal, Montréal, Canada.

出版信息

J Dual Diagn. 2020 Apr-Jun;16(2):191-207. doi: 10.1080/15504263.2020.1726549. Epub 2020 Feb 23.

Abstract

Depression is the most common psychiatric comorbidity among people with opioid use disorders (OUDs). However, whether and how comorbid depression is associated with the outcomes of opioid agonist therapy (OAT) remains poorly understood. The objective of this review was to identify and describe the association between depression and main outcomes (opioid use and treatment retention) of methadone and buprenorphine treatment among people with OUDs. A literature review was conducted by searching five electronic databases (MEDLINE, PubMed, Embase, Evidence-Based Medicine Reviews [EBMR], and Cumulative Index of Nursing and Allied Health Literature [CINAHL] Complete) from January 1970 to April 2019. Two independent reviewers screened titles and abstracts of the identified records by using pre-established eligibility criteria. Next, full texts were reviewed and studies that met inclusion criteria were selected. Finally, a descriptive synthesis of extracted data was performed. In total, 12,296 records were identified and 18 studies that met inclusion criteria were retained. Of these, six studies reported reduced opioid use and seven reported increased opioid use during methadone or buprenorphine treatment. In addition, three studies reported an increased retention rate and four documented a decreased retention rate during methadone or buprenorphine treatment. The remaining studies did not find any significant association between depression and opioid use or treatment retention. Overall, the evidence did not demonstrate a consistent association between depression and outcomes of methadone or buprenorphine treatment. Although the inconsistent nature of the current evidence prohibited us from drawing definitive conclusions, we posit that the presence of depression among OUDs patients may not always predict negative outcomes related to retention and drug use during the course of OAT. Particularly, the hypothesis that adequate treatment of depression can improve treatment retention is promising and is in line with the call for increased efforts to provide integrated care for comorbid mental health disorders and addiction. Future studies with rigorous methodology are essential to better characterize the complex interplay between depression, OAT, and OUDs.

摘要

抑郁症是阿片类物质使用障碍(OUD)患者中最常见的精神共病。然而,共病抑郁症与阿片类激动剂治疗(OAT)结果之间的关联,以及这种关联的方式,仍知之甚少。本综述的目的是确定并描述抑郁症与OUD患者美沙酮和丁丙诺啡治疗的主要结果(阿片类物质使用和治疗保留率)之间的关联。通过检索1970年1月至2019年4月期间的五个电子数据库(MEDLINE、PubMed、Embase、循证医学综述[EBMR]和护理及相关健康文献累积索引[CINAHL]完整版)进行文献综述。两名独立的评审人员使用预先确定的纳入标准筛选已识别记录的标题和摘要。接下来,对全文进行评审,并选择符合纳入标准的研究。最后,对提取的数据进行描述性综合分析。总共识别出12296条记录,保留了18项符合纳入标准的研究。其中,六项研究报告美沙酮或丁丙诺啡治疗期间阿片类物质使用减少,七项研究报告阿片类物质使用增加。此外,三项研究报告美沙酮或丁丙诺啡治疗期间保留率增加,四项研究记录了保留率下降。其余研究未发现抑郁症与阿片类物质使用或治疗保留率之间存在任何显著关联。总体而言,证据并未表明抑郁症与美沙酮或丁丙诺啡治疗结果之间存在一致的关联。尽管当前证据的不一致性使我们无法得出明确结论,但我们认为,OUD患者中抑郁症的存在可能并不总是预示着与OAT过程中的治疗保留率和药物使用相关的负面结果。特别是,充分治疗抑郁症可以提高治疗保留率这一假设很有前景,并且符合呼吁加大力度为共病心理健康障碍和成瘾提供综合护理的要求。未来采用严谨方法的研究对于更好地描述抑郁症、OAT和OUD之间复杂的相互作用至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验